EVMN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025
Revenue
0
0
0
Cost of Revenue
0
0
0
Gross Profit
0
0
0
Operating Expenses
34.9M
+45.7%
24.0M
-19.4%
29.7M
R&D
26.4M
+52.5%
17.3M
-15.1%
20.4M
SG&A
8.5M
+27.9%
6.6M
-28.8%
9.3M
Operating Income
-34895000
-45.7%
-23954000
+19.4%
-29716000
EBITDA
-34343000
-45.5%
-23605000
+19.7%
-29390000
Net Income
-32246000
-48.8%
-21674000
+23.3%
-28273000
EPS (Basic)
$-0.89
-39.1%
$-0.64
+54.9%
$-1.42
EPS (Diluted)
$-0.89
-39.1%
$-0.64
+54.9%
$-1.42
Shares (Diluted)
36.1M
+7.3%
33.7M
+69.0%
19.9M
Evommune (EVMN) โ€” Financials